2021
Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2020
Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyProceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop
Yu JB, Brock KK, Campbell AM, Chen A, Diaz R, Escorcia F, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood B, Woodward WA. Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 539-545. PMID: 32434040, DOI: 10.1016/j.ijrobp.2020.05.018.Peer-Reviewed Original Research
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspective
2016
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop
Smith G, Ganz P, Bekelman J, Chmura S, Dignam J, Efstathiou J, Jagsi R, Johnstone P, Steinberg M, Williams S, Yu J, Zietman A, Weichselbaum R, Shih Y. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. International Journal Of Radiation Oncology • Biology • Physics 2016, 97: 450-461. PMID: 28011046, PMCID: PMC6044722, DOI: 10.1016/j.ijrobp.2016.10.042.Peer-Reviewed Original ResearchMeSH KeywordsCosts and Cost AnalysisDecision MakingDiffusion of InnovationHumansNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionNeoplasmsProgram EvaluationProton TherapyRadiation OncologyRadiotherapyRadiotherapy, Intensity-ModulatedResearch PersonnelTechnology, RadiologicUnited StatesConceptsRadiation oncology communityRadiation oncology treatmentsRadiation oncologyAdvanced radiation technologiesOncology communityOncological treatmentNational Cancer Policy Forum of the National Academies of SciencesNational Cancer Policy ForumPractice of radiation oncologyRadiation oncology practiceProspective registry dataCancer care decisionsGeneration of scientific evidenceRadiation therapyScientific evidenceEvidence-based effortsComparative effectiveness dataCancer careClinical effectsCare decisionsQuality benchmark dataDe-adoptionRegistry dataThe National Academy of SciencesOncology practice
2014
Radiation Therapy Defnitions and Reporting Guidelines for Thymic Malignancies
Gomez D, Komaki R, Yu J, Ikushima H, Bezjak A. Radiation Therapy Defnitions and Reporting Guidelines for Thymic Malignancies. Chinese Journal Of Lung Cancer 2014, 17: 110-115. PMID: 24581161, PMCID: PMC6131239, DOI: 10.3779/j.issn.1009-3419.2014.02.08.Peer-Reviewed Original Research
2010
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation
Galper S, Yu J, Mauch P, Strasser J, Silver B, LaCasce A, Marcus K, Stevenson M, Chen M, Ng A. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2010, 117: 412-418. PMID: 20858859, DOI: 10.1182/blood-2010-06-291328.Peer-Reviewed Original ResearchConceptsStandardized incidence ratioClinically significant cardiac diseaseSignificant cardiac diseaseMediastinal irradiationAbsolute excess riskCardiac eventsCardiac proceduresIncidence rate of cardiac eventsCardiac diseaseRate of cardiac eventsExcess riskSurvivors of Hodgkin lymphomaCoronary artery bypass graftingMedian follow-upCox regression analysisArtery bypass graftingCumulative incidence rateAssociated with excess riskImplantable cardioverter defibrillatorHodgkin lymphomaRadiation therapyValve surgeryCardiac surveillanceCardiac complicationsPacemaker placement